share_log

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $69

Benzinga Real-time News ·  Sep 12, 2022 06:52

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $68 to $69.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment